Clinical Trial Update: CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

The clinical trial of CYNK-101 in combination with trastuzumab and pembrolizumab for HER2-positive gastric or gastroesophageal junction cancer has been terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• CYNK-101
• KEYTRUDA (PEMBROLIZUMAB)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Celularity Incorporated | Conditions: Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1, Phase 2 | Status: TERMINATED